{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:21:22Z","timestamp":1787757682396,"version":"build-2784847793"},"reference-count":50,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 AR074534"],"award-info":[{"award-number":["K24 AR074534"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01 HS028024"],"award-info":[{"award-number":["R01 HS028024"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>CVS Caremark changed their national commercial formularies in 2024 to prefer adalimumab\u2010adaz over originator. We assessed the formulary change's effect on biosimilar adalimumab prescribing in US community rheumatology practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data come from Rheumatology Informatics System for Effectiveness, a registry of electronic health record data from participating community rheumatology practices nationwide. We used interrupted time series to analyze the effect of the CVS formulary change on the proportion of patients prescribed adalimumab\u2010adaz or other adalimumab biosimilars each month between January 2023 and September 2024 stratified by payor and among new users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 22,079 patients. Among those commercially insured, prescriptions for adalimumab\u2010adaz went from nearly 0% to more than 25% following the CVS formulary change. In the next month, prescriptions for adalimumab\u2010adaz dropped 12.3%. Prescriptions for other biosimilars increased slowly and linearly over the study period. Among patients with Medicare, we observed a similarly timed, but much smaller, increase in prescribing for both adalimumab\u2010adaz and other biosimilar molecules without a large subsequent decrease. Among new users, prescriptions for adalimumab\u2010adaz increased from 0% to 24% but was followed by a nearly 14% decrease in prescriptions in the first month after the formulary change. Other biosimilar prescriptions increased 0.6% per month throughout the period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although biosimilar adalimumab prescriptions rose sharply after a major national formulary change, the increase was not sustained. These findings highlight that persistent barriers, including the nocebo effect and the administrative burden of switching, may continue to limit biosimilar adoption and contribute to the loss of substantial cost savings in the US market.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.80024","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:38:24Z","timestamp":1771238304000},"page":"1287-1297","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Major\n                    <scp>US<\/scp>\n                    Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing"],"prefix":"10.1002","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8435-8994","authenticated-orcid":false,"given":"Eric T.","family":"Roberts","sequence":"first","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-5043","authenticated-orcid":false,"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"},{"name":"San Francisco Veterans Affairs Medical Center  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Clark","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ung","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"},{"name":"Zuckerberg San Francisco General Hospital  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"e_1_2_6_2_1","article-title":"Biosimilars in the United States 2023\u20102027: competition, savings, and sustainability","author":"IQVIA Institute","year":"2023","journal-title":"IQVIA."},{"key":"e_1_2_6_3_1","article-title":"Express scripts adds three biosimilars to largest formulary to promote competition and advance affordability, choices for patients","author":"PR Newswire","year":"2023","journal-title":"PR Newswire."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2322"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2019.668"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-025-01192-x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.54111\/0001\/bb2"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4753"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.6.600"},{"key":"e_1_2_6_10_1","unstructured":"RobertsET SchmajukG YazdanyJ.Very low uptake of biosimilar adalimumab in the first 9 months of availability in rheumatology. Paper presented at: ACR Convergence 2024; November 17 2024; Washington DC. Accessed May 20 2025.https:\/\/acrabstracts.org\/abstract\/very\u2010low\u2010uptake\u2010of\u2010biosimilar\u2010adalimumab\u2010in\u2010the\u2010first\u20109\u2010months\u2010of\u2010availability\u2010in\u2010rheumatology\/"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00447-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.8917"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42963"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2022.00812"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14410"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.15872"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002173\u20107"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2025.00443"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11634"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.00366"},{"key":"e_1_2_6_22_1","volume-title":"Pharmacy Benefit Manager (PBM) Overview","author":"Bates H","year":"2025"},{"key":"e_1_2_6_23_1","article-title":"Pharmacy benefit management concepts: processes and strategies","author":"National CooperativeRx","year":"2024","journal-title":"National CooperativeRx."},{"key":"e_1_2_6_24_1","article-title":"The top pharmacy benefit managers of 2024: market share and key industry developments","author":"Fein AJ","year":"2025","journal-title":"Drug Channels"},{"key":"e_1_2_6_25_1","article-title":"CVS Caremark to replace Humira with biosimilars on national commercial formularies","author":"Volansky R.","year":"2024","journal-title":"Healio."},{"key":"e_1_2_6_26_1","article-title":"CVS Caremark's policy shift on Humira biosimilars may not be what the doctor ordered","author":"Cohen JP","year":"2024","journal-title":"Forbes."},{"key":"e_1_2_6_27_1","article-title":"CVS Caremark accelerates biosimilars adoption through formulary changes","author":"CVS Health","year":"2024","journal-title":"CVS Health"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23089"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.160221"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25318"},{"key":"e_1_2_6_31_1","article-title":"STDDIFF: Stata module to compute standardized differences for continuous and categorical variables","author":"Bayoumi AM","year":"2022","journal-title":"Statistical Software Components S458275. Boston College Department of Economics"},{"issue":"12","key":"e_1_2_6_32_1","first-page":"700","article-title":"Interpreting estimates of treatment effects: implications for managed care","volume":"33","author":"Faraone SV","year":"2008","journal-title":"P T"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500208"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25099"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.14363"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.05.026"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42520"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02818-9"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24114"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11617"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.952"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-024-00541-y"},{"key":"e_1_2_6_43_1","article-title":"Adalimumab biosimilar tracking Q1 readout","author":"IQVIA","year":"2024","journal-title":"SCRIBD"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa502"},{"key":"e_1_2_6_45_1","unstructured":"Cardinal Health.2023 biosimilars report.2023. Accessed October 15 2024.https:\/\/www.cardinalhealth.com\/content\/dam\/corp\/web\/documents\/Report\/cardinal-health-biosimilars-report-2023.pdf"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70020"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34776"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4324"},{"key":"e_1_2_6_49_1","article-title":"Unraveling PBM complexity: the consequences of vertical integration","author":"SmithRx","year":"2024","journal-title":"SmithRx."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.3964"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24104"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.80024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:49:51Z","timestamp":1787755791000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.80024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/acr.80024"],"URL":"https:\/\/doi.org\/10.1002\/acr.80024","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}